ARRAY BIOPHARMA INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth.
At the same time, stockholders' equity ("net worth") has greatly increased by 164.13% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||16.2||6.07|
|Net Income ($mil)||-20.99||-27.59|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||0.0||110.7|
|Total Assets ($mil)||186.75||135.33|
|Total Debt ($mil)||108.81||105.26|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||61.65||-86.21|
|Return on Assets||8.55||-71.8|
|Return on Equity||66.28||0.0|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||142.11||131.83|
|Div / share||0.0||0.0|
|Book value / share||0.17||-0.29|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2001613.0||1655325.0|
SELL. ARRAY BIOPHARMA INC's P/E ratio indicates a significant premium compared to an average of 47.43 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 21.93. For additional comparison, its price-to-book ratio of 23.95 indicates a significant premium versus the S&P 500 average of 2.77 and a significant premium versus the industry average of 16.75. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ARRAY BIOPHARMA INC proves to trade at a premium to investment alternatives within the industry.
|ARRY 58.00||Peers 47.43||ARRY NA||Peers 42.69|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
ARRY is trading at a premium to its peers.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|ARRY NM||Peers 19.59||ARRY NM||Peers 0.56|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ARRY's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
ARRY's negative PEG ratio makes this valuation measure meaningless.
|ARRY 23.95||Peers 16.75||ARRY 109.21||Peers 14.89|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ARRY is trading at a significant premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ARRY is expected to have an earnings growth rate that significantly exceeds its peers.
|ARRY 4.06||Peers 289.74||ARRY 318.78||Peers 60.69|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ARRY is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
ARRY has a sales growth rate that significantly exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas